SCHEMBL2853618

SCHEMBL2853618

CC(C)(C#N)Oc1cccc(C(=O)O)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK3 Q15120 1/20 0.40
PDK4 Q16654 1/20 0.40
BRAF P15056 3/20 0.39
KDR P35968 3/20 0.39
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
HSD17B10 Q99714 3/20 0.38
HPGD P15428 2/20 0.38
ESR1 P03372 1/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38
HMGB1 P09429 1/20 0.38
GGT1 P19440 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2858446 0.88 BRAF (0.39) TSHRPDK1PDK2PDK3PDK4
SCHEMBL2861153 0.86 PDK1 (0.45) TSHRPDK1PDK2PDK3PDK4
SCHEMBL2125517 0.84 KDM4E (0.50) TSHRMAPK1ALDH1A1KDM4EHSD17B10
SCHEMBL6022582 0.76 TSHR (0.52) TSHRPDK1PDK2PDK3PDK4
SCHEMBL993218 0.74 HTT (0.58) TSHRMAPK1ALDH1A1KDM4EHSD17B10
SCHEMBL825860 0.74 TSHR (0.49) TSHRPDK1PDK2PDK3PDK4
Hydrochloric Acid SCHEMBL25281166 0.73 HTT (0.56) TSHRMAPK1ALDH1A1KDM4EHSD17B10
SCHEMBL7835343 0.72 TSHR (0.59) TSHRMAPK1ALDH1A1KDM4EHSD17B10
SCHEMBL9340184 0.72 TSHR (0.59) TSHRMAPK1ALDH1A1KDM4EHSD17B10
SCHEMBL6693412 0.71 KDM4E (0.68) TSHRMAPK1ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 TSHR 2511/4885PDK1 479/4885PDK2 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.